Functional and motor response to low dose olanzapine in Huntington's disease: Case report

Arquivos de Neuro-Psiquiatria

Volumn 62, Issue 4, 2004, Pages 1092-1094

  Laks, Jerson ^a,b,e   Rocha, Marios ^a   Capitão, Claudia ^a   Côrtes Domingues, Romeu ^c   Ladeia, Giovanna ^c   Lima, Maurido ^d,e   Engelhardt, Eliasz ^a  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b STATE UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^c Clinica Multi imagem e Ressonancia   (Brazil)

^d FEDERAL UNIVERSITY OF PELOTAS   (Brazil)

^e Fed Univ Pelotas/Cathol Univ P ^*  (Brazil)

Author keywords

Behavioral abnormalities; Functional capacity; Huntington's disease; Olanzapine

Indexed keywords

OLANZAPINE;

ADULT; ARTICLE; BEHAVIOR DISORDER; CASE REPORT; DAILY LIFE ACTIVITY; DELUSION; DRUG EFFICACY; FEMALE; FOLLOW UP; HUMAN; HUNTINGTON CHOREA; LOW DRUG DOSE; NEUROLOGIC EXAMINATION; NUCLEAR MAGNETIC RESONANCE IMAGING; PSYCHOMOTOR ACTIVITY; RATING SCALE;

EID: 10944263498     PISSN: 0004282X     EISSN: None     Source Type: Journal    
DOI: 10.1590/S0004-282X2004000600030     Document Type: Article

References (13)

1. Gusella JF, Wexler NS, Connealy PM, et al. A polymorphic DNA marker genetically linked to Huntington's disease. Nature 1983;306:234.
2. Gilliam TC, Tanzi RE, Haines JL, et al. Localization of the Huntington's disease gene to a small segment of chromosome 4 flanked by D4S10 and the telomere. Cell 1987;50:565.
3. Cummings JL. Subcortical dementia. New York / Oxford, Oxford Univ Press, 1990.
4. Dipple HC. The use of olanzapine for movement disorder in Huntington's disease: a first case report. J Neurol Neurosurg Psychiatry 1999;67:123-124.
5. Squitieri F, Cannella M, Piorcellini A, et al. Short-term effects of olanzapine in Huntington's disease. Neuropsychiatry Neuropsychol Behav Neurol 2001;14:69-72.
6. Bonelli RM, Niederwieser G, Tribl GG, et al. High-dose olanzapine in Huntington's disease. Int Clin Psychopharmacol 2002;17:91-93.
7. Paleacu D, Anca M, Giladi N. Olanzapine in Huntington's disease. Acta Neurol Scand 2002;105:441-444.
8. Jiménez-Jiménez FJ, Toledo M, Puertas I, et al. La olanzapina mejora el corea en pacientes con enfermedad de Huntington. Rev Neurol 2002;35:524-525.
9. Huntington Study Group. Unified Huntington's disease Rating Scale: reliability and consistency. Mov Disord 1996;11:136-142.
10. Bonelli RM, Mahnert FA, Niederwieser G. Olanzapine for Huntington disease: an open label study. Clin Neuropharmachol 2002;25:263-265.
11. Grove VE Jr, Quintanilla J, DeVaney GT. Improvement of Huntington's disease with olanzapine and valproate. N Engl J Med 2000;343:973-974.
12. Folstein SE, Jensen B, Leigh RJ, et al. The measurement of abnormal movement: methods developed for Huntington's disease. Neurobehav Toxicol Teratol 1983;5:605-609.
13. Etchebehere EC, Lima MC, Passos W, et al. Brain SPECT imaging in Huntington's disease before and after therapy with olanzapine: case report. Arq Neuropsiquiatr 1999;57:863-866.